Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). (Q49141898)
Jump to navigation
Jump to search
scientific article published on 4 May 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). |
scientific article published on 4 May 2015 |
Statements
1 reference
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). (English)
1 reference
J Vansteenkiste
F Barlesi
C F Waller
J Bennouna
C Gridelli
E Goekkurt
D Verhoeven
A Szczesna
M Feurer
P Germonpre
H Lena
D Atanackovic
C Hicking
J Straub
M Picard
4 May 2015
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference